BridgeBio Pharma reported multiple late‑stage successes this week, with its oral candidate encaleret meeting all primary and key secondary endpoints in autosomal dominant hypocalcemia type 1 (ADH1). The company reported that 76% of treated patients achieved normalized serum and urine calcium at 24 weeks versus 4% on standard care; encaleret also corrected parathyroid hormone levels in the majority of responders. BridgeBio is preparing regulatory filings next year and cited tolerability consistent with ADH1 biology. The company also logged a separate late‑stage win for BBP‑418 in limb‑girdle muscular dystrophy, underpinning a rare‑disease momentum that analysts say could reshape commercial prospects acrossBridgeBio’s portfolio. Management linked these data to an improving commercial trajectory after earlier struggles, noting Attruby sales and positioning the company to pursue multiple regulatory submissions and potential label expansions for underserved genetic disorders.